arrow
A

Andrew M. Intlekofer

Memorial Sloan Kettering Cancer Center
H指数:34
被引数:9,956

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma

晚期高级别B细胞淋巴瘤的临床结局、复发模式和分子景观

2026-07-130
OA
Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma

二十年单机构数据揭示复发/难治性伯基特淋巴瘤的罕见长期生存者

2026-01-011
OA
Corrigendum to ‘Systemic metabolic changes in acute and chronic lymphocytic choriomeningitis virus infection’ [Mol Metab Volume 99 (2025) Article 102194]

勘误:‘急性与慢性淋巴细胞脉络丛脑膜炎病毒感染的系统代谢变化’ [Mol Metab 卷 99(2025)文章 102194]

2025-07-310
OA
Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab和Entinostat治疗复发/难治性霍奇金淋巴瘤的II期试验最终应答和生存结果

BLOOD
IF23.1
2024-11-051
PRE
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

具有MYC,BCL2和/或BCL6重排的有限阶段高级别b细胞淋巴瘤: BCL2重排导致不良结果

2024-10-140
OAAI
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience

利妥昔单抗和来那度胺治疗复发或难治性惰性非霍奇金淋巴瘤的现实经验

2024-09-050
OAAI
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
2024-05-160
OAAI
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI
OncoTree: A Cancer Classification System for Precision Oncology
2021-12-0167
OA